🇺🇸 FDA
Pipeline program

Zanubrutinib

IIT2023063

Phase 1 small_molecule active

Quick answer

Zanubrutinib for Chronic Lymphocytic Leukemia is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials